| 51 |
20712135 | Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells. | 2010 |
1 |
| 52 |
20714791 | Statins attenuate high mobility group box-1 protein induced vascular endothelial activation : a key role for TLR4/NF-κB signaling pathway. | 2010 Dec |
1 |
| 53 |
20953062 | Sympathoinhibition by atorvastatin in hypertensive patients. | 2010 Nov |
1 |
| 54 |
19067673 | (TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients. | 2009 Mar |
2 |
| 55 |
19237515 | Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. | 2009 May |
1 |
| 56 |
20069794 | Solubility and stability enhancement of atorvastatin by cyclodextrin complexation. | 2009 May-Jun |
1 |
| 57 |
17651990 | Automated enzyme inhibition assay method for the determination of atorvastatin-derived HMG-CoA reductase inhibitors in human plasma using radioactivity detection. | 2008 Jan-Feb |
1 |
| 58 |
18261731 | The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg. | 2008 Sep |
1 |
| 59 |
18303938 | Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. | 2008 |
2 |
| 60 |
18395165 | Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia. | 2008 May |
1 |
| 61 |
18547436 | Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. | 2008 Jun 11 |
1 |
| 62 |
18720283 | Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. | 2008 Sep |
1 |
| 63 |
17261740 | Clinical trials of neuroprotective therapies. | 2007 Feb |
1 |
| 64 |
17529847 | Effect of atorvastatin on progression of sensorineural hearing loss and tinnitus in the elderly: results of a prospective, randomized, double-blind clinical trial. | 2007 Jun |
1 |
| 65 |
17622571 | Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. | 2007 Oct 1 |
4 |
| 66 |
16503719 | Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors. | 2006 Mar |
1 |
| 67 |
16554298 | Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. | 2006 Jun 2 |
1 |
| 68 |
19804188 | Atorvastatin: beyond lipid-lowering effects in the diabetic population. | 2006 Sep |
1 |
| 69 |
15962651 | Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level. | 2005 Mar |
1 |
| 70 |
16020911 | Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. | 2005 |
1 |
| 71 |
16185099 | A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus? | 2005 |
1 |
| 72 |
16284747 | Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). | 2005 Dec |
1 |
| 73 |
16327254 | Lipids and stroke: the opportunity of lipid-lowering treatment. | 2005 |
1 |
| 74 |
16356805 | Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. | 2005 Dec |
1 |
| 75 |
16356809 | A rationale for combination therapy in risk factor management: a mechanistic perspective. | 2005 Dec |
1 |
| 76 |
16360444 | Atorvastatin: a potential chemopreventive agent in bladder cancer. | 2005 Dec |
1 |
| 77 |
14684313 | An efficient synthesis of N3,4-diphenyl-5-(4-fluorophenyl)-2-isopropyl-1H-3-pyrrolecarboxamide, a key intermediate for atorvastatin synthesis. | 2004 Jan 5 |
1 |
| 78 |
15381079 | Beta4 integrin is involved in statin-induced endothelial cell death. | 2004 Oct 22 |
1 |
| 79 |
15488897 | The effect of high glucose on NO and O2- through endothelial GTPCH1 and NADPH oxidase. | 2004 Nov 12 |
1 |
| 80 |
12612140 | Red wine polyphenolics increase LDL receptor expression and activity and suppress the secretion of ApoB100 from human HepG2 cells. | 2003 Mar |
1 |
| 81 |
12612979 | A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. | 2003 Mar |
1 |
| 82 |
12648031 | An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS). | 2003 |
1 |
| 83 |
12816876 | Low-level endotoxin induces potent inflammatory activation of human blood vessels: inhibition by statins. | 2003 Sep 1 |
1 |
| 84 |
12960612 | Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. | 2003 Sep |
1 |
| 85 |
14564679 | Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. | 2003 Oct |
1 |
| 86 |
14578459 | Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. | 2003 Oct |
1 |
| 87 |
14687410 | Atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces bone resorption in the elderly. | 2003 Nov |
1 |
| 88 |
11772327 | Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. | 2002 Jan |
1 |
| 89 |
11831546 | Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. | 2002 Feb |
1 |
| 90 |
11887170 | Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. | 2002 Mar |
1 |
| 91 |
11918754 | A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. | 2002 Apr |
1 |
| 92 |
12017409 | A preliminary evaluation of neural network analysis for pharmacodynamic modeling of the dosing of the hydroxymethylglutaryl coenzyme A-reductase inhibitors simvastatin and atorvastatin. | 2002 Apr |
1 |
| 93 |
12145183 | Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin. | 2002 Aug |
1 |
| 94 |
12181212 | Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia. | 2002 Sep |
1 |
| 95 |
12426205 | 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. | 2002 Nov 1 |
1 |
| 96 |
12433810 | Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. | 2002 Dec |
1 |
| 97 |
12494218 | [Effect of atorvastatin on endothelial function in patients with familial hypercholesterolemia]. | 2002 |
1 |
| 98 |
12769127 | Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. | 2002 Mar |
1 |
| 99 |
11336625 | Atorvastatin. | 2001 May |
2 |
| 100 |
11474489 | Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. | 2001 Aug |
1 |